Storgate LLC Invests $738,000 in Becton, Dickinson and Company $BDX

Storgate LLC bought a new position in Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, Holdings Channel.com reports. The firm bought 3,802 shares of the medical instruments supplier’s stock, valued at approximately $738,000. Becton, Dickinson and Company accounts for about 0.6% of Storgate LLC’s portfolio, making the stock its 27th largest holding.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Milford Funds Ltd. bought a new stake in Becton, Dickinson and Company in the fourth quarter valued at $52,300,000. Broyhill Asset Management LLC bought a new stake in Becton, Dickinson and Company in the fourth quarter valued at $207,000. Wealthspire Advisors LLC boosted its holdings in Becton, Dickinson and Company by 26.8% in the fourth quarter. Wealthspire Advisors LLC now owns 6,350 shares of the medical instruments supplier’s stock valued at $1,232,000 after acquiring an additional 1,342 shares in the last quarter. Summit Financial LLC boosted its holdings in Becton, Dickinson and Company by 30.8% in the fourth quarter. Summit Financial LLC now owns 3,212 shares of the medical instruments supplier’s stock valued at $623,000 after acquiring an additional 757 shares in the last quarter. Finally, Westchester Capital Management Inc. boosted its holdings in Becton, Dickinson and Company by 0.9% in the fourth quarter. Westchester Capital Management Inc. now owns 47,365 shares of the medical instruments supplier’s stock valued at $9,192,000 after acquiring an additional 419 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on BDX. Weiss Ratings cut shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. BofA cut their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday. Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Piper Sandler cut their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Finally, TD Cowen cut their price target on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a report on Monday, May 4th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $182.73.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total transaction of $166,628.00. Following the completion of the transaction, the executive vice president owned 14,272 shares of the company’s stock, valued at approximately $2,161,922.56. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This represents a 2.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,013 shares of company stock valued at $593,434 in the last three months. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $146.13 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $40.27 billion, a P/E ratio of 37.00, a P/E/G ratio of 10.43 and a beta of 0.22. The business has a fifty day simple moving average of $150.00 and a two-hundred day simple moving average of $174.05. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.